Chelation Therapy

Are heavy metals weighing you down?

The concern with heavy metals is that they can potentially accumulate in the body over time and are suspected of triggering dangerous conditions like heart disease, thyroid problems, autoimmune conditions, neurological conditions such as dementia, Alzheimer’s, and autism.  Doctor Jordan Atkinson is seeing a growing trend of patients with heavy metals in their bodies contributing to an array of health problems.

Why would we have heavy metals in our body?

Reasons for high levels of heavy metals can vary from: lead based toys we played with as children, smoking, poor air quality, paint, GMO foods, farm raised fish, vaccinations, mercury or amalgam fillings, and even our water supply.  Some people have more difficulty removing heavy metals from the body than others.


What are some signs or symptoms of high heavy metal levels:

  • Chronic fatigue syndrome
  • Trouble learning and remembering new information
  • “Brain fog” and trouble concentrating
  • Autoimmune diseases
  • Neur3-1ological disorders and cognitive decline
  • Joint or muscle pain
  • Mood changes, including depression and anxiety
  • Alopecia
  • Cardiovascular disease
  • Dermatitis
  • Poor wound healing
  • Gastrointestinal symptoms
  • Hypertension
  • Low immune function
  • Impaired glucose tolerance
  • Inflammation
  • Parkinson’s-like symptoms

How do you test for heavy metals?

Acute metal poisoning is not common. However, we typically see chronic, low-level exposure to toxic metals that can result in significant retention in the body that can be associated with a vast array of adverse health effects and chronic disease.

Dr. Jordan performs both a pre- and post-provocation urinalysis to determine if there is ongoing exposures to metals (pre-) and net bodily retention of heavy metals.

How long has chelation therapy been used?

Chelation therapy is derived from the Greek word CHELE meaning claw of a crab. A chelating agent grabs onto an electrically charged mineral ion such as lead, copper, iron or calcium. EDTA is a chelating agent that was developed in Germany in the 1930’s. EDTA was first used for the treatment of lead poisoning.  Many doctors found additional benefits when chelating with EDTA, such as improvement with arthritis and atherosclerosis.  The use of intravenous chelation therapy is to reverse hardening of the arteries, and degenerative diseases.

Two-time Nobel Prize winner, Dr. Linus Pauling had this to say about Chelation:

“Chelation therapy is far safer and much less expensive than surgical treatment of atherosclerosis. Chelation therapy might eliminate the need for bypass surgery and is equally valid when used as a preventative treatment.”

How does chelation work?

Chelation therapy involves the use of a chelating agent to bind and eliminate undesirable substances such as heavy metals, chemical toxins, mineral deposits and fatty plaques. These agents can also help to improve circulation and enhance the immune system.

Chelation can be done through oral dimercaptosuccinic acid (DMSA), or intravenous ethylenediaminetetraacetic acid (EDTA).  Dr. Jordan uses DMSA or EDTA depending which heavy metals are elevated in the body. EDTA binds very well with lead, and DMSA binds very well with mercury.

What is the best way to describe chelation?

Dr. Jordan describes chelation as a powerful magnet for toxic metals.

Chelating agents have specific bonds that form between metals and organic molecules. This gives the chelating agent the ability to “bind” to metals that build up in the blood, major organs and blood vessels.

How often are the treatments?

Dr. Jordan does treatments usually once to twice a week.  The amount of treatments vary depending on the levels of heavy metals found in the body, however, Dr Jordan usually does 10-30 treatments depending on the levels of heavy metals. For more information call Aumakua Integrated Wellness Clinic at 604-684-6565 to book an Initial Consultation with Dr. Jordan!

4-1Dr. Jordan’s FUN FACT:

Did you know, increasing the diameter of an artery by 15% will double the blood flow through the artery!!!

Dr. Jordan believes in being proactive, not reactive, in one’s health. He works with his patients to identify the cause(s) of his/her illness. He then creates an individualized treatment protocol, tailored to meet his patient’s specific needs. Dr. Jordan uses cutting-edge diagnostic labs and therapeutic modalities to enhance the healing process. Dr. Jordan participates in continuing medical education in order to ensure that his patients receive current and optimal safe health care.

Dr. Jordan is an outdoors enthusiast and can often be found skiing, hiking, and playing soccer on the weekends. Dr. Jordan grew up in the Okanagan and now lives on the Northshore with his wife and son.


Aumakua Integrated Wellness Clinic
Downtown Vancouver Chelation Therapy
604-684-6565
Day & Evening Appointments Available
#209 – 970 Burrard Street (Electra Building)


References:

Arom KV, Cohen DE, Strobl FT. Effect of intraoperative intervention on neurological outcome based on electroencephalographic monitoring during cardiopulmonary bypass. Ann Thorac Surg. 1988;48:476-483.

Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988;27:41-49.

Holliday HJ. Carotid restenosis: A case for EDTA chelation. J Adv Med. 1996;9.

Parisi AF, Folland ED, Hartigan PA. Comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326:10-16.

Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med. 1993;6:139-160.

Schachter MB. Overview, historical background and current status of EDTA chelation therapy for atherosclerosis. J Adv Med.1996;9:159-177.

Gundy P. Cardiovascular diseases remain nation’s leading cause of death. JAMA. 1992;267:335-336.

Winslow CM, Kosecoff JB, Chassin M, Kanouse DE, Brook RH. The appropriateness of performing coronary artery bypass surgery.JAMA. 1988;260:505-509.

Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci.1956;December:654-666.

Meltzer LE, Ural E, Kitchell JR. The treatment of coronary artery heart disease with disodium EDTA. In: Seven M, ed. Metal-Binding in Medicine. Philadelphia: JB Lippincott; 1960.

Edmunds LH, Stephenson LW, Edie RN, Ratcliffe MB. Open-heart surgery in octogenarians. N Engl J Med. 1988;319:131-136.

CASS Principal Investigators and the Associates. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery: Survival data. Circulation. 1983;68:939-950.

CASS Principal Investigators and the Associates. Myocardial infarction and mortality in the Coronary Artery Surgery Study randomized trial. N Engl J Med. 1984;310:750-758.

Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs. 1996;10:78-86.

Cashin WL, Sanmarco ME, Nessim SA, Blankenhorn DH. Accelerated progression of atherosclerosis in coronary vessels with minimal lesions that are bypassed. N Engl J Med. 1984;311:824-828.

Rudolph CJ, Samuels RT, McDonagh EW. Visual field evidence of macular degeneration reversal using a combination of EDTA chelation and multiple vitamin and trace mineral therapy. J Adv Med. 1994;7:203-212.

Casdorph HR. EDTA chelation therapy, II: efficacy in brain disorders. J Holist Med. 1981;3:101-117.

Casdorph HR. EDTA chelation therapy: efficacy in arteriosclerotic heart disease. J Holist Med. 1981;3:53-59.

Hancke C, Flytie K. Benefits of EDTA chelation therapy on arteriosclerosis. J Adv Med. 1993;6:161-172.

Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988;27:41-49.

Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc. 1990;82:173-174.

Rudolph CJ, McDonagh EW, Barber RK. A non-surgical approach to obstructive carotid stenosis using EDTA chelation. J Adv Med.1991;4:157-166. Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg. 1991;162:122-125.

Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication – a double-blind, placebo-controlled study. J Intern Med. 1992;231:261-267.

van Rij AM, Solomon C, Packer SGK, Hopkins WG. Chelation therapy for intermittent claudication: a double-blind, randomized, controlled trial. Circulation. 1994;90:1194-1199.

KEEP UP TO DATE

Sign up to receive our newsletter